128 related articles for article (PubMed ID: 499319)
1. Influence of the defective metabolism of sparteine on its pharmacokinetics.
Eichelbaum M; Spannbrucker N; Dengler HJ
Eur J Clin Pharmacol; 1979 Sep; 16(3):189-94. PubMed ID: 499319
[TBL] [Abstract][Full Text] [Related]
2. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
Eichelbaum M; Spannbrucker N; Steincke B; Dengler HJ
Eur J Clin Pharmacol; 1979 Sep; 16(3):183-7. PubMed ID: 499318
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine.
Mikus G; Ha HR; Vozeh S; Zekorn C; Follath F; Eichelbaum M
Eur J Clin Pharmacol; 1986; 31(1):69-72. PubMed ID: 3780830
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation.
Zekorn C; Achtert G; Hausleiter HJ; Moon CH; Eichelbaum M
Klin Wochenschr; 1985 Nov; 63(22):1180-6. PubMed ID: 4079282
[TBL] [Abstract][Full Text] [Related]
5. The influence of enzyme induction on polymorphic sparteine oxidation.
Eichelbaum M; Mineshita S; Ohnhaus EE; Zekorn C
Br J Clin Pharmacol; 1986 Jul; 22(1):49-53. PubMed ID: 3741726
[TBL] [Abstract][Full Text] [Related]
6. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.
Brøsen K; Davidsen F; Gram LF
Br J Clin Pharmacol; 1990 Feb; 29(2):248-53. PubMed ID: 2306418
[TBL] [Abstract][Full Text] [Related]
7. Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.
Nielsen F; Rosholm JU; Brøsen K
Eur J Clin Pharmacol; 1995; 48(6):501-4. PubMed ID: 8582470
[TBL] [Abstract][Full Text] [Related]
8. Non-linear pharmacokinetics of sparteine in the rat.
Van der Graaff M; Vermeulen NP; Koperdraat MC; Breimer DD
Arch Int Pharmacodyn Ther; 1986 Aug; 282(2):181-95. PubMed ID: 3767526
[TBL] [Abstract][Full Text] [Related]
9. Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype.
Gross AS; Mikus G; Fischer C; Hertrampf R; Gundert-Remy U; Eichelbaum M
Br J Clin Pharmacol; 1989 Nov; 28(5):555-66. PubMed ID: 2511912
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.
Herchuelz A; Gangji D; Derenne F; Jeanniot JP; Douchamps J
Br J Clin Pharmacol; 1991 Jan; 31(1):73-6. PubMed ID: 2015173
[TBL] [Abstract][Full Text] [Related]
12. A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.
Nielsen MD; Brøsen K; Gram LF
Br J Clin Pharmacol; 1990 Mar; 29(3):299-304. PubMed ID: 2310654
[TBL] [Abstract][Full Text] [Related]
13. Deficient metabolism of debrisoquine and sparteine.
Inaba T; Otton SV; Kalow W
Clin Pharmacol Ther; 1980 Apr; 27(4):547-9. PubMed ID: 7357813
[TBL] [Abstract][Full Text] [Related]
14. The genetic polymorphism of sparteine metabolism.
Eichelbaum M; Reetz KP; Schmidt EK; Zekorn C
Xenobiotica; 1986 May; 16(5):465-81. PubMed ID: 3739368
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.
Sindrup SH; Brøsen K; Gram LF
Clin Pharmacol Ther; 1992 Mar; 51(3):288-95. PubMed ID: 1531951
[TBL] [Abstract][Full Text] [Related]
16. Evidence for polymorphic oxidation of sparteine in Japanese subjects.
Ishizaki T; Eichelbaum M; Horai Y; Hashimoto K; Chiba K; Dengler HJ
Br J Clin Pharmacol; 1987 Apr; 23(4):482-5. PubMed ID: 3580254
[TBL] [Abstract][Full Text] [Related]
17. Sparteine oxidation is practically abolished in quinidine-treated patients.
Brinn R; Brøsen K; Gram LF; Haghfelt T; Otton SV
Br J Clin Pharmacol; 1986 Aug; 22(2):194-7. PubMed ID: 3756067
[TBL] [Abstract][Full Text] [Related]
18. Factors affecting the kinetics of two benzothiazine non-steroidal anti-inflammatory medicines, piroxicam and isoxicam.
Edwards IR; Ferry DG; Campbell AJ
Eur J Clin Pharmacol; 1985; 28(6):689-92. PubMed ID: 4065194
[TBL] [Abstract][Full Text] [Related]
19. Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH.
Gross AS; Mikus G; Fischer C; Eichelbaum M
Eur J Clin Pharmacol; 1991; 40(2):155-62. PubMed ID: 1906003
[TBL] [Abstract][Full Text] [Related]
20. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
